Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer.
Naoto Tada UenoRie K TaharaTakeo FujiiJames M ReubenHui GaoBabita SaigalAnthony LucciToshiaki IwaseNuhad K IbrahimSenthil DamodaranYu ShenDiane D LiuGabriel N HortobagyiDebu TripathyBora LimBeth A ChasenPublished in: Cancer medicine (2019)
Ra-223 with hormonal therapy showed possible efficacy in HR+ bone-dominant breast cancer metastasis, and adverse events were tolerable. We plan to further investigate the clinical application of Ra-223 in these patients. (NCT02366130).
Keyphrases
- phase ii study
- metastatic breast cancer
- end stage renal disease
- rheumatoid arthritis
- bone mineral density
- newly diagnosed
- ejection fraction
- chronic kidney disease
- polycystic ovary syndrome
- disease activity
- soft tissue
- prognostic factors
- ankylosing spondylitis
- peritoneal dialysis
- stem cells
- clinical trial
- bone marrow
- systemic sclerosis
- randomized controlled trial
- interstitial lung disease
- metabolic syndrome
- adipose tissue
- bone regeneration
- cell therapy
- childhood cancer